Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $50
Express News | Tandem T:Slim X2 Insulin Pump Now Compatible With Dexcom G7 Cgm in Canada
Tandem T:slim X2 Insulin Pump Now Compatible With Dexcom G7 CGM in Canada
Express News | Tandem Diabetes Care Inc : Canaccord Genuity Raises Target Price to $63 From $56
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $40
Tandem Diabetes Care Poised for Growth: Expansion Into Type 2 Diabetes and Strategic Integration Drive Buy Rating
Tandem Diabetes Care (TNDM) Down 9.2% Since Last Earnings Report: Can It Rebound?
United States Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring BD, Roche, Medtronic, Insulet, Abbott, Dexcom, Tandem Diabetes Care, Ypsomed Novo Nordisk, Eli Lilly - ResearchAndMarkets.com
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Tandem Diabetes Care Raised to Overweight From Equal-Weight by Morgan Stanley
Morgan Stanley Upgrades Tandem Diabetes Care(TNDM.US) to Buy Rating, Maintains Target Price $45
Leerink Partners Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Express News | Tandem Diabetes Care Inc : Leerink Partners Cuts Target Price to $58 From $59
This Insider Has Just Sold Shares In Tandem Diabetes Care
Tandem Diabetes Care Announces Upcoming Conference Presentations
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
Assessing MedTech Impact From Potential China Tariffs
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $60